Loading...
Market
Will BlueBird Bio's gene therapy for sickle cell disease receive Medicare coverage by the end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Medicare or CMS (Centers for Medicare & Medicaid Services)
Story
12-Year-Old Kendric Cromer Receives $2.2 Million Gene Therapy for Sickle Cell Disease
Sep 16, 2024, 11:50 PM
Kendric Cromer, a 12-year-old boy, has become one of the first children to be treated with a newly approved gene therapy for sickle cell disease. This treatment, developed by BlueBird Bio, offers hope for a cure and a future free from the excruciating pain that has characterized his life. However, the high cost of the treatment, priced at $2.2 million, poses significant challenges. Insurers are hesitant to cover the expense, and hospitals are wary of the financial burden. The approval of this gene therapy by the FDA marks a significant milestone, but accessibility remains a critical issue for many patients. Deepak Srivastava highlights the broader issue of how to pay for breakthrough cures.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Safety warning update • 25%
Clinical trial halt • 25%
No action • 25%
Other action • 25%
New England Journal of Medicine • 25%
Journal of the American Medical Association • 25%
The Lancet • 25%
Other • 25%
Improved survival rates • 25%
Increased cancer rates • 25%
Stable condition • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $500,000 • 25%
$500,000 to $750,000 • 25%
$750,000 to $1,000,000 • 25%
More than $1,000,000 • 25%